TOKYO, Nov 2 (Reuters) - Takeda Pharmaceutical Co. Ltd. (4502.T: Quote, NEWS, Research), Japan’s largest drug maker, on Thursday dropped development of a drug for nerve disorders caused by diabetes but also said it would tie up with U.S. biotech firm Xoma (XOMA.O: Quote, Profile, Research) to develop monoclonal antibodies.
